TSCAN THERAPEUTICS, INC. Total Long-Term Debt
TSCAN THERAPEUTICS, INC. (TCRX) had Total Long-Term Debt of $32.78 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-08-12
- 2026-06-30: Long-term Debt $32.78M.
- 2026-03-31: Long-term Debt $32.65M.
- 2025-12-31: Long-term Debt $32.53M.
- 2025-09-30: Long-term Debt $32.41M.
| Period end | Long-term Debt |
|---|---|
| 2026-06-30 | $32.78M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $32.65M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $32.53M 10-K · filed 2026-03-04 |
| 2025-09-30 | $32.41M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $32.30M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $32.18M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $32.07M 10-K · filed 2025-03-05 |
| 2024-09-30 | $30.65M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $30.45M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $30.25M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $30.05M 10-K · filed 2024-03-06 |
| 2023-09-30 | $29.95M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $29.72M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $29.50M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $29.29M 10-K · filed 2023-03-08 |
| 2022-09-30 | $29.07M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |